Universal Vaccine Shows Promise in Preventing Respiratory Infections
A new “universal” vaccine, demonstrating effectiveness against a broad range of respiratory infections – including COVID-19, influenza, and even antibiotic-resistant bacteria – has shown promising results in animal testing, according to research published in the journal Science on February 19, 2026.1
How This Vaccine Differs from Traditional Approaches
Traditional vaccines typically target specific pathogens. This new vaccine takes a different approach, aiming to stimulate a broad immune response within the lungs. Researchers found that the vaccine activates macrophages, a type of white blood cell, leading to a highly activated immune response.1
Key Findings from Animal Studies
- The vaccine was effective against the SARS-CoV-2 virus (COVID-19) and Staphylococcus aureus for at least three months in animal models.1
- It similarly demonstrated a protective effect against other viruses, including SARS and SHC014 coronavirus.1
- Notably, the vaccine showed efficacy against Acinetobacter baumannii, a multi-drug resistant bacteria that poses a significant threat in hospital settings.1
- Vaccinated mice rapidly developed pathogen-specific T cell and antibody responses, forming structures within the lungs that enhance immune function.1
- The number of viruses infiltrating the lungs and body was reduced by a factor of 100 to 1000 in vaccinated mice, with the immune system eradicating the remaining viruses quickly.1
Mechanism of Action
The vaccine is administered via a nasal spray, directly targeting the mucosal lining of the lungs. This method stimulates the immune system to mount a robust defense against a wide array of respiratory pathogens. According to Professor Bali Pullendran of Stanford University School of Medicine, the vaccine is protective against “virtually all viruses…and all the many types of bacteria that we’ve tested, and even allergens.”1
Previous Research and Context
The development of this vaccine builds upon previous research exploring the potential for broad-spectrum immune stimulation. Studies have suggested that the BCG vaccine (for tuberculosis) may offer some protection against viral infections, although clinical trial results have been mixed.1 Similarly, the oral polio vaccine and measles vaccine have been investigated for their potential to induce broader protective effects.1 Research conducted by Professor Pullendran and colleagues in 2021 and 2024, studying immune responses to the flu vaccine and BCG vaccine, laid the groundwork for this new universal vaccine.1
Future Research
The research team is now focused on testing the effectiveness of this “universal vaccine” in human clinical trials.1